Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
List view / Grid view
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
An artificial intelligence technique can identify which neoantigens are recognised by the immune system, possibly improving cancer prognosis and treatment.
New research has revealed that club cells secret anti-immunosuppressive factors in tumours, potentially revolutionising cancer therapies.
Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
Scientists have developed a “llama nanobody” that is capable of chasing out human cytomegalovirus (HCMV) so it is detected by the immune system.
Researchers have used patient-specific tumour organoid models to improve immunotherapy treatments for appendiceal cancer.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.